Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases

• Published in: Respirology (Carlton, Vic.) Vol. 27; no. 4; pp. 294 - 300
• Main Authors: Brown, Kevin K., Inoue, Yoshikazu, Flaherty, Kevin R., Martinez, Fernando J., Cottin, Vincent, Bonella, Francesco, Cerri, Stefania, Danoff, Sonye K., Jouneau, Stephane, Goeldner, Rainer‐Georg, Schmidt, Martin, Stowasser, Susanne, Schlenker‐Herceg, Rozsa, Wells, Athol U.
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01.04.2022; Wiley Subscription Services, Inc; Wiley
• Subjects: Carbon monoxide; clinical trial; Clinical trials; death; Disease Progression; fibrosing interstitial lung disease; Fibrosis; forced vital capacity; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Life Sciences; Lung; Lung diseases; Lung Diseases, Interstitial; Mortality; Original; ORIGINAL ARTICLES; pulmonary fibrosis; pulmonary function test; Vital Capacity; clinical trial; death; pulmonary function test; fibrosing interstitial lung disease; forced vital capacity; pulmonary fibrosis
• ISSN: 1323-7799; 1440-1843; 1440-1843
• DOI: 10.1111/resp.14231

Background and objective Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) and the INBUILD trial in subjects with other progressive fibrosing ILDs to assess relationships between demographic/clinical variables and mortality. Methods The relationships between baseline variables and time‐varying covariates and time to death over 52 weeks were analysed using pooled data from the INPULSIS trials and, separately, the INBUILD trial using a Cox proportional hazards model. Results Over 52 weeks, 68/1061 (6.4%) and 33/663 (5.0%) subjects died in the INPULSIS and INBUILD trials, respectively. In the INPULSIS trials, a relative decline in forced vital capacity (FVC) >10% predicted within 12 months (hazard ratio [HR] 3.77) and age (HR 1.03 per 1‐year increase) were associated with increased risk of mortality, while baseline FVC % predicted (HR 0.97 per 1‐unit increase) and diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 0.77 per 1‐unit increase) were associated with lower risk. In the INBUILD trial, a relative decline in FVC >10% predicted within 12 months (HR 2.60) and a usual interstitial pneumonia‐like fibrotic pattern on HRCT (HR 2.98) were associated with increased risk of mortality, while baseline DLCO % predicted (HR 0.95 per 1‐unit increase) was associated with lower risk. Conclusion These data support similarity in the course of lung injury between IPF and other progressive fibrosing ILDs and the value of FVC decline as a predictor of mortality. We assessed relationships between baseline and time‐varying factors and mortality over 52 weeks in 1061 subjects with idiopathic pulmonary fibrosis (IPF) and 663 subjects with other progressive fibrosing interstitial lung diseases (ILDs). Our findings support similarity in the course of IPF and ILD and an association between decline in forced vital capacity and mortality.